These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33141411)

  • 1. Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review.
    Artime E; Qizilbash N; Herruzo R; Garrido-Estepa M
    Pharmaceut Med; 2020 Dec; 34(6):387-400. PubMed ID: 33141411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional risk minimisation measures in the EU - are they eligible for assessment?
    Zomerdijk IM; Trifirò G; Sayed-Tabatabaei FA; Sturkenboom MC; Straus SM
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1046-53. PubMed ID: 23946274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder.
    Agyemang E; Bailey L; Talbot J
    Pharmaceut Med; 2017; 31(2):101-112. PubMed ID: 28413313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies.
    Vora P; Artime E; Soriano-Gabarró M; Qizilbash N; Singh V; Asiimwe A
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):695-706. PubMed ID: 29663572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register.
    Farcas A; Huruba M; Mogosan C
    Br J Clin Pharmacol; 2019 Mar; 85(3):476-491. PubMed ID: 30497102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept (ORENCIA) patient alert cards in patients with rheumatoid arthritis.
    Artime E; Kahlon R; Méndez I; Kou T; Garrido-Estepa M; Qizilbash N
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):664-674. PubMed ID: 32394485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union.
    Hoeve CE; Francisca RDC; Zomerdijk I; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2020 Jan; 43(1):45-55. PubMed ID: 31617081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
    Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.
    Rees S; Williams A
    JBI Libr Syst Rev; 2009; 7(13):492-582. PubMed ID: 27819974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of internet-based e-learning on clinician behavior and patient outcomes: a systematic review protocol.
    Sinclair P; Kable A; Levett-Jones T
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):52-64. PubMed ID: 26447007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
    Francisca RDC; Baba E; Hoeve CE; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2021 Jan; 44(1):63-72. PubMed ID: 33000427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are risk minimization measures for approved drugs in Europe effective? A systematic review.
    Artime E; Qizilbash N; Garrido-Estepa M; Vora P; Soriano-Gabarró M; Asiimwe A; Pocock S
    Expert Opin Drug Saf; 2019 May; 18(5):443-454. PubMed ID: 31032651
    [No Abstract]   [Full Text] [Related]  

  • 15. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
    Abou Taam M; Ferard C; Rocle P; Maison P
    Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.
    Banerjee AK; Zomerdijk IM; Wooder S; Ingate S; Mayall SJ
    Drug Saf; 2014 Jan; 37(1):33-42. PubMed ID: 24357107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe.
    Mayall S; Kahlon R; Al-Dakkak I; Shen SW
    Pharmaceut Med; 2021 Mar; 35(2):123-135. PubMed ID: 33660230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet.
    Artime E; Shui I; Mendez I; Tcherny-Lessenot S; D'Arbigny P; Alfaro N; Qizilbash N
    Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):103-110. PubMed ID: 31667955
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.